Pages that link to "Q46408397"
Jump to navigation
Jump to search
The following pages link to Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma (Q46408397):
Displaying 11 items.
- Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. (Q33576476) (← links)
- Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme (Q35027024) (← links)
- Innovative Therapies against Human Glioblastoma Multiforme (Q35374492) (← links)
- Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies (Q35623965) (← links)
- Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations (Q35986801) (← links)
- EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells (Q36310662) (← links)
- Anti-cancer Therapies in High Grade Gliomas (Q37290626) (← links)
- Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study (Q39217123) (← links)
- Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics (Q41885614) (← links)
- The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma (Q47868509) (← links)
- Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib (Q48687589) (← links)